Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Queensland Health

Generated: September 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 10,189,837

  Try a free trial

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,189,837 protect, and when does it expire?

Patent 10,189,837 protects TALZENNA and is included in one NDA.

This patent has twenty-six patent family members in sixteen countries.

Summary for Patent: 10,189,837
Title:Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Abstract: Provided herein are (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt forms, including crystalline forms, and methods of their preparation. Pharmaceutical compositions comprising a (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt are also provided, as are methods of using (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,- 9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt to treat a disease or condition, such as a cancer.
Inventor(s): Wang; Bing (San Jose, CA), Chu; Daniel (Santa Clara, CA), Liu; Yongbo (Shanghai, CN), Peng; Shichun (Shanghai, CN)
Assignee: Medivation Technologies LLC (San Francisco, CA)
Application Number:15/651,735
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 10,189,837

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-001 Oct 16, 2018 RX Yes No   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
Pfizer Inc TALZENNA talazoparib tosylate CAPSULE;ORAL 211651-002 Oct 16, 2018 RX Yes Yes   Try a Free Trial   Try a Free Trial Y Y   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 10,189,837

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 083502   Try a Free Trial
Australia 2011317040   Try a Free Trial
Australia 2017201564   Try a Free Trial
Brazil 112013009117   Try a Free Trial
Canada 2814581   Try a Free Trial
China 103282365   Try a Free Trial
European Patent Office 2630146   Try a Free Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.